Scholarlink

Background <p>Lenvatinib is the first-line therapy for advanced hepatocellular carcinoma (HCC). Nevertheless, drug resistance is a challenge for improving the outcomes of these patients. Discs Large Homolog Associated Protein 5 (DLGAP5) belongs to cell-cycle-regulated proteins, associated with poor prognosis in cancer. However, its biological roles and mechanisms in lenvatinib sensitivity of HCC remain unclear.</p> Methods <p>We analyzed the expression level of DLGAP5 by public database. A sixty HCC patients’ cohort was used to investigate the prognostic potential after lenvatinib treatment. Cell growth, metastasis, apoptosis, and animal experiments were used to explore the specific function of DLGAP5. Differentially expressed genes of DLGAP5-knockdown cells were analyzed by RNA-seq data.</p> Results <p>DLGAP5 was upregulated in HCC tissues, especially in lesions of patients with metastasis. Overexpression of DLGAP5 correlated with poor prognosis and lower response to lenvatinib treatment. We found that the downregulation of DLGAP5 inhibited malignancy and increased the sensitivity of HCC cells to lenvatinib both in vitro and in vivo. Mechanistically, DLGAP5 might function by regulating AKT/mTOR/NF-κB signaling pathway.</p> Conclusions <p>DLGAP5 promotes malignancy of HCC and reduces cell lenvatinib sensitivity by positively regulating the AKT/mTOR/NF-κB pathway, indicating that DLGAP5 functions as a potential biomarker for clinical prognosis and lenvatinib treatment in HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DLGAP5 regulates malignancy and lenvatinib sensitivity of hepatocellular carcinoma through AKT/mTOR/NF-κB pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月9日

查看全文
  • Benyi He,
  • Min Deng,
  • Renguo Guan,
  • Jie Mei,
  • Hao Zou,
  • Yuhao Tang,
  • Zhenyun Yang,
  • Zehao Zheng,
  • Wenping Lin,
  • Shaohua Li,
  • Rongping Guo,
  • Rongce Zhao,
  • Wei Wei

摘要

Background

Lenvatinib is the first-line therapy for advanced hepatocellular carcinoma (HCC). Nevertheless, drug resistance is a challenge for improving the outcomes of these patients. Discs Large Homolog Associated Protein 5 (DLGAP5) belongs to cell-cycle-regulated proteins, associated with poor prognosis in cancer. However, its biological roles and mechanisms in lenvatinib sensitivity of HCC remain unclear.

Methods

We analyzed the expression level of DLGAP5 by public database. A sixty HCC patients’ cohort was used to investigate the prognostic potential after lenvatinib treatment. Cell growth, metastasis, apoptosis, and animal experiments were used to explore the specific function of DLGAP5. Differentially expressed genes of DLGAP5-knockdown cells were analyzed by RNA-seq data.

Results

DLGAP5 was upregulated in HCC tissues, especially in lesions of patients with metastasis. Overexpression of DLGAP5 correlated with poor prognosis and lower response to lenvatinib treatment. We found that the downregulation of DLGAP5 inhibited malignancy and increased the sensitivity of HCC cells to lenvatinib both in vitro and in vivo. Mechanistically, DLGAP5 might function by regulating AKT/mTOR/NF-κB signaling pathway.

Conclusions

DLGAP5 promotes malignancy of HCC and reduces cell lenvatinib sensitivity by positively regulating the AKT/mTOR/NF-κB pathway, indicating that DLGAP5 functions as a potential biomarker for clinical prognosis and lenvatinib treatment in HCC.